Why Is Tempus AI (TEM) Stock Up +10.67% Today?
Key Takeaways
- TEM shares jumped 10.67% to close at $68.85, up $6.64 from the prior session's close of $62.21.
- The rally was driven primarily by a Piper Sandler analyst upgrade to Overweight, with the price target raised from $56 to $76.
- Secondary catalysts included the FDA clearance of the tumor-only xT CDx test and favorable INTerpath-001 study results tied to the Personalis acquisition.
- The move reflects renewed optimism around Tempus AI's precision-medicine and data-licensing growth story.
- Traders are watching upcoming earnings, FDA milestones, and the closing of the Personalis transaction for further direction.
Opening Summary
Tempus AI, Inc. (TEM), a healthcare technology company that applies artificial intelligence to precision medicine through oncology diagnostics, data licensing, and clinical trial matching, surged in Tuesday's session. Shares climbed 10.67% to close at $68.85, a gain of $6.64 versus the previous close of $62.21. The upward move marked a sharp reversal from a recent stretch of weakness and was attributed by markets to a bullish analyst upgrade combined with a series of regulatory and clinical developments that reinforced the company's growth narrative.
Analyst Upgrade Sparks the Rally
The most direct catalyst for the day's surge was an upgrade from Piper Sandler, which lifted its rating on TEM from Neutral to Overweight while raising its price target from $56 to $76. The analyst shift reflected an evolving view that Tempus AI's valuation is increasingly supported by tangible business fundamentals rather than pure artificial-intelligence enthusiasm. The upgrade highlighted three specific drivers: the pending acquisition of Personalis, favorable INTerpath-001 study results, and FDA clearance of the xT CDx test.
FDA Clearance and Clinical Momentum
Regulatory and clinical news reinforced the analyst's more constructive stance. The Food and Drug Administration's clearance of the tumor-only xT CDx test removes a key hurdle for Tempus AI as it pursues unified ADLT pricing across its xT product portfolio, a move management has said could add meaningful incremental average selling price lift. Separately, favorable results from the INTerpath-001 study were seen as elevating the strategic importance of both Tempus AI and its acquisition target, Personalis, positioning the company more firmly in the minimal residual disease (MRD) sequencing market. The company also announced FDA approval for an AI product that uses standard electrocardiogram data to identify signs of pulmonary arterial hypertension, extending its AI footprint into cardiovascular diagnostics.
Personalis Acquisition in Focus
The pending acquisition of Personalis remained a central theme in Tuesday's trading. The transaction, under which each Personalis share is valued at $16.25 in Tempus Class A stock with an option for partial cash consideration, would give Tempus AI a tumor-informed MRD platform that analysts have characterized as a distinctive asset in oncology diagnostics. With the S-4 filing submitted and the deal expected to close in late 2026 or early 2027, the market has begun pricing in the strategic and revenue implications of combining the two platforms.
Market Context and Trading Activity
The rally unfolded within a broader climate of renewed interest in healthcare AI and precision-medicine names, where Tempus AI has stood out for its durable diagnostic volume growth and a data-licensing business that has posted several consecutive quarters of strong bookings. The company's recent earnings beat, in which revenue rose roughly 22% year-over-year alongside a narrower-than-expected loss, provided a supportive fundamental backdrop even as the stock had pulled back from prior highs. The sharp single-day gain pushed TEM decisively back above levels where it had consolidated in recent sessions, though the stock remains well below its 52-week high of $104.32.
What Comes Next for TEM
Looking ahead, investors will monitor Tempus AI's next quarterly earnings report for confirmation that oncology volume and data-licensing momentum continue at recent growth rates. Key upcoming milestones include the expected closing of the Personalis acquisition and further regulatory progress on liquid biopsy and companion diagnostic pathways, which management has flagged as longer-term growth levers. Risks include execution around the integration of acquisitions, reimbursement dynamics, and the broader sensitivity of high-multiple AI and growth stocks to shifting market sentiment. As with any sharp move, traders will watch whether the rally holds or consolidates near newly reclaimed technical levels.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing automated trading strategies under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols, but only those demonstrating standout results are featured in this section. Explore the Trending AI Robots to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TEM sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for TEM moved above the 200-day moving average on September 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on TEM as a result. In 30 of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
Following a +9.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in 110 of 125 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 48 of 54 cases where TEM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Bearish Trend Analysis
The 10-day RSI Indicator for TEM moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 14 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TEM turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In 21 of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TEM broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (34.722) is very high in comparison to the industry average of (7.432). P/E Ratio (39.298) is within average values for comparable stocks, (46.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (8.696) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement